Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times ...
Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists. This is an ASCO Meeting Abstract from the ...
Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored This study of mutation testing in patients with NSCLC 25 and other studies that are measuring other genetic ...
The GSI 39 provides a flexible, screening product for tympanometry, acoustic reflex measurements, and audiometry to meet testing needs today and in the future. The GSI 39 is available in five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results